Though the second quarter didn’t function any life sciences enforcement motion by the FTC, there was loads of information in and across the house. The FTC held an in depth “digital workshop” as a part of its pharmaceutical merger job pressure and information emerged of a possible Merck-Seagen deal that would arrange an fascinating check… Continue reading Antitrust + Competition Life Sciences Quarterly Update – Q2 2022 | Goodwin